Login to Your Account



Production woes halt newly revving Auryxia sales, dent Keryx's Q2

By Jennifer Boggs
Managing Editor

Monday, August 1, 2016

With reimbursement issues in the rearview mirror and efforts from an amped-up sales force finally starting to yield momentum, Keryx Biopharmaceuticals Inc.'s second-quarter earnings should have been a resounding message of reassurance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription